CET specializes in stem cell research, tissue engineering and cancer biology. We develop media, provide and conduct research on stem cells obtained from human non-embryonic sources, such as adipose tissue, bone marrow, Wharton’s jelly, umbilical cord blood, and placentas. In addition, CET's mission is to be a leading provider of induced pluripotent (IPS) stem cells derived from normal human volunteers and patients with various clinical conditions. Our engineering focus is on preclinical drug discovery and high throughput drug screening and discovery applications for various human diseases. CET's cancer biology focus is on the isolation and culture of solid tumors from cancers of the breast, colon, kidney, lung and prostate.
Alan Moy, MD
Chief Executive Officer and Founder
Alan Moy, M.D., a physician-scientist, was previously on faculty for 13
years at the University of Iowa Department of Internal Medicine and
Biomedical Engineering. Dr. Moy founded the company in 2000. Dr. Moy
received a Bachelor's degree in Biochemistry from the University of
California, Davis and an M.D. from Creighton University. He received postgraduate education in Internal Medicine from
St. Louis University and completed a fellowship in Pulmonary Medicine and Critical Care Medicine at
the University of Iowa. Dr. Moy's research expertise is in the area of
vascular biology and tissue engineering. Dr. Moy is also listed in the 2010 Who's Who in America and is listed in 2011 as a Leading Physician of the World by the International Association of Healthcare Professions.
Social Media Links: